Cellectis (NASDAQ:CLLS) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS) in a report published on Friday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Barclays dropped their target price on Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th.

Cellectis Stock Performance

Shares of Cellectis stock opened at $2.10 on Friday. The business has a 50-day simple moving average of $1.95 and a 200 day simple moving average of $2.17. The firm has a market capitalization of $116.72 million, a price-to-earnings ratio of -1.62 and a beta of 3.10. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.78 and a quick ratio of 1.78. Cellectis has a one year low of $1.70 and a one year high of $3.77.

Cellectis (NASDAQ:CLLS) last posted its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.03). The business had revenue of $18.05 million during the quarter, compared to analyst estimates of $5.00 million. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. During the same period in the previous year, the business posted ($0.31) EPS. On average, research analysts anticipate that Cellectis will post -0.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cellectis

A number of hedge funds have recently made changes to their positions in CLLS. XTX Topco Ltd bought a new position in shares of Cellectis during the 2nd quarter valued at approximately $29,000. First Affirmative Financial Network bought a new position in shares of Cellectis during the 3rd quarter worth $45,000. Principal Financial Group Inc. lifted its holdings in Cellectis by 2.9% during the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after purchasing an additional 12,467 shares during the last quarter. Finally, Long Focus Capital Management LLC lifted its holdings in Cellectis by 2.9% during the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after purchasing an additional 130,000 shares during the last quarter. 63.90% of the stock is currently owned by institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.